Adelaide J, Monges G, Derderian C, Seitz JF and Birnbaum D (1995). Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. Br. J. Cancer, 71, 64-68.
Alao JP (2007). The regulation of cyclin D1 degradation: role in cancer development and potential for therapeutic invention. Molecular Cancer, 6, 1-16.
Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A and Pestell RG (1995). Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem., 270, 23589-23597.
Anderson D, Koch CA, Grey L, Ellis C, Moran MF and Pawson T (1990). Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors. Science, 250, 979-982.
Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, Wang S, Weinstein IB and Holt PR (1996). Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology, 110, 669-674.
Chang, U. M. (2005). 靈芝醇抗癌機制的研究:抑制拓樸異構酶及引導肝癌細胞走向老化 [master's thesis, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU.2005.00593